NeuroSense Therapeutics Ltd.
NASDAQ: NRSN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Alon Ben-Noon
- Employees
- 17
- Headquarters
- Herzliya, Israel
- IPO year
- 2021
- Market cap
- $18.7M
- Website
- https://www.neurosense-tx.com
Loading NRSN…
Loading profile data…Frequently asked questions about NRSN
What does NeuroSense Therapeutics Ltd. (NRSN) do?
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa...
Where does NRSN trade?
NeuroSense Therapeutics Ltd. (NRSN) trades on the NASDAQ Capital Market.
What sector is NRSN in?
NeuroSense Therapeutics Ltd. (NRSN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of NeuroSense Therapeutics Ltd.?
Alon Ben-Noon is the chief executive officer of NeuroSense Therapeutics Ltd. (NRSN).
Where is NeuroSense Therapeutics Ltd. headquartered?
NeuroSense Therapeutics Ltd. is headquartered in Israel.
Does NRSN pay a dividend?
NeuroSense Therapeutics Ltd. (NRSN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NRSN go public?
NeuroSense Therapeutics Ltd. (NRSN) completed its initial public offering in 2021.